论文部分内容阅读
[目的]探讨PARP1在可手术非小细胞肺癌组织中的表达情况及其临床预后价值。[方法]采用免疫组化法对81例非小细胞肺癌患者手术标本进行PARP1蛋白表达的定量分析;运用卡方检验对PARP1表达结果与临床参数间进行比较,其中分期情况视为等级资料采用Wilcoxon秩和检验;采用Cox回归及Kaplan-Meier生存分析曲线评价PARP1对可手术非小细胞肺癌的临床预后价值。[结果]81例非小细胞肺癌患者组织样本中PARP1蛋白表达水平与性别、年龄、吸烟状况、病理类型、淋巴结转移状况等临床参数之间无统计学差异(P>0.05)。81例患者中PARP1阳性标本中表达量为(+)、(++)、(≥+++)样本比例分别为33.33%(13/39)、35.90%(14/39)、30.77%(12/39)。Cox多因素分析结果显示,在76例具有完整生存随访资料患者中,PARP1表达情况与患者无疾病生存期相关,PARPI阴性表达组及阳性表达组DFS分别为36.2个月和23.5个月(Cox多因素分析结果P=0.003);但与总生存期无关,PARP1阴性表达组及阳性表达组OS分别为49.6个月和44.0个月(Cox多因素分析P=0.341)。[结论]PARP1阴性可手术的非小细胞肺癌患者在接受手术后可能获得较长的无疾病生存期,但可能并不能转化为总生存期上的获益。
[Objective] To investigate the expression of PARP1 in operable non-small cell lung cancer and its clinical prognostic value. [Methods] Immunohistochemical method was used to quantitatively analyze the expression of PARP1 protein in surgical specimens of 81 patients with non-small cell lung cancer. The chi-square test was used to compare PARP1 expression results with clinical parameters. The staging status was regarded as grade data using Wilcoxon. Rank sum test; Cox regression and Kaplan-Meier survival analysis curve to evaluate the clinical prognostic value of PARP1 in operable non-small cell lung cancer. [Results] No significant difference was found in the expression of PARP1 protein and the gender, age, smoking status, pathological type, lymph node metastasis and other clinical parameters in 81 cases of non-small cell lung cancer (P>0.05). Among the 81 patients, the positive rate of PARP1 positive samples was (+), (++), (≥+++). The proportions of the samples were 33.33% (13/39), 35.90% (14/39), and 30.77% (12). /39). Cox multivariate analysis showed that in 76 patients with complete survival follow-up data, the expression of PARP1 was associated with disease-free survival. The DFS of PARPI-negative and positive-expression groups was 36.2 months and 23.5 months, respectively (Cox Factor analysis (P=0.003); however, irrespective of overall survival, the PARP1 negative expression group and the positive expression group were 49.6 months and 44.0 months, respectively (Cox multivariate analysis P=0.341). [Conclusion] Patients with PARP1-negative operable non-small cell lung cancer may have longer disease-free survival after surgery, but may not be able to translate into overall survival benefits.